SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

RARE

Ultragenyx Pharmaceutical Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The Q1 miss may pressure the stock near-term, but focus should shift to upcoming PDUFA decisions and GTX-102 Phase 3 readout. Traders should weigh the weak quarter against pipeline catalysts; a beat on any of these could reverse sentiment.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.93
T+0 close · May 5, 2026 · via day close
Latest settled
−3.93%
T+60 · $24.91
Vs SPY
−5.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $25.93entry
  2. T+1 · 6mo ago 0.00%α +0.33% · $25.93
  3. T+5 · 6mo ago +3.51%α +2.38% · $26.84
  4. T+20 · 6mo ago −13.57%α −16.36% · $22.41
  5. T+60 · 4mo ago −3.93%α −5.99% · $24.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expectations. Despite reaffirming full-year 2026 guidance of $730M-$760M revenue, the weak quarter and wider operating loss of $305M signal near-term headwinds, though upcoming PDUFA dates for DTX401 and UX111 provide potential catalysts.

Key Financial Metrics

EPS
−$1.84
est −$1.46 · -26.0%
Revenue
$136.0M
est $158.4M · -14.1% · -2.2% YoY
Rating
strong miss
Guidance
$730M-$760M
maintained
Gross Margin
77.94%

Key Facts

  • Q1 2026 revenue $136M, down 2.2% YoY from $139M, missing consensus $158.4M
  • Q1 2026 EPS -$1.84 vs consensus -$1.46; net loss $185M vs $151M YoY
  • Reaffirmed full-year 2026 revenue guidance $730M-$760M and expense guidance
  • R&D expenses $187M, up from $166M YoY; SG&A $88M flat
  • Total operating expenses $305M included $30M restructuring and $30M stock-based compensation
  • Cash and securities $534M; net cash used in operations $197M
  • Two BLAs under FDA review with PDUFA dates: DTX401 (Aug 23, 2026) and UX111 (Sep 19, 2026)
  • Phase 3 GTX-102 Angelman data expected H2 2026

Financial Impact

Revenue miss of ~$22M (14%) vs consensus; EPS miss of -$0.38 (26%) vs consensus

revenueepsoperating losscash burn

Risk Factors

  • FDA delays or rejections for DTX401 or UX111
  • Competition in Angelman syndrome and gene therapy
  • Continued cash burn and need for additional financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3288196

Track record

22 reports on RARE

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 7h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026